Alvarez & Marsal (A&M) announced the launch of its Life Sciences Business Unit. Designed to help address industry challenges and provide comprehensive solutions, A&M’s Life Sciences Business Unit leverages the firm’s integrated platform and represents its next milestone for delivering inventive solutions and driving sustainable growth.
Managing Director and Life Sciences Practice Leader, Mark Freitas, is joined by Life Sciences Business Unit Managing Directors Jim Cleffi, David Martin, Rich Rieger, and Matt Sheldon; alongside Senior Directors Daaron Dohler, Seth Rogers, and Matt Staffier. Collectively, this leadership team brings deep industry expertise, spanning over a century of combined experience across diverse disciplines and sectors including pharmaceuticals, biotechnology, biopharma, medical devices, medical technology, digital health, and pharma services.
Leveraging A&M’s operational heritage along with its in-depth corporate finance, strategic planning, board governance, mergers and acquisitions activity, risk management, and compliance knowledge, the Life Sciences Business Unit will help clients navigate an intricate industry landscape while capitalizing on opportunities.
Tom Elsenbrook, Managing Director and leader of A&M’s Corporate Performance Improvement group, highlighted the importance of redefining life sciences’ business operations against the backdrop of a shifting industry environment. "A&M’s Life Science Business Unit, combines the firm’s legacy capabilities with its strong sector knowledge. Our results-driven mindset and customized solutions focus will help clients accelerate the development and commercialization of groundbreaking products.”
Martin McGahan, a Managing Director and Head of Alvarez & Marsal’s Healthcare Industry Group, said, “The Life Sciences Business Unit is a natural evolution of our in-depth healthcare sector knowledge and our ability to drive changes that achieve clients’ goals and meet market demands. The team’s combined expertise aligns with the firm’s operational orientation and augments our ability to develop sustainable solutions that promote growth.”
Freitas said, “A&M has developed an innovative approach to helping life sciences clients maximize value. An evolving industry landscape combined with a volatile economy requires an outcomes-driven approach that meets the urgency of clients’ current demands and anticipates those of tomorrow. The Life Sciences Business Unit launch marks a significant milestone for A&M, reinforcing the firm's commitment to help clients bring purposeful innovations to market.”